Beam looks to accelerated approval for AATD base editing after promising updatenews2026-03-25T15:31:38+00:00March 25th, 2026|Endpoints News|
Microneedle vaccine patch company raises $50M for pivot to GLP-1 deliverynews2026-03-25T13:00:28+00:00March 25th, 2026|Endpoints News|
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertexnews2026-03-25T11:02:18+00:00March 25th, 2026|Endpoints News|
Ocugen heads to Phase 3 with gene therapy for geographic atrophynews2026-03-24T15:40:16+00:00March 24th, 2026|Endpoints News|
Biotech investors set to meet with key congressional panelnews2026-03-24T12:00:02+00:00March 24th, 2026|Endpoints News|
Immutrin secures $86M for antibody programnews2026-03-24T07:00:02+00:00March 24th, 2026|Endpoints News|
Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryonnews2026-03-23T15:16:14+00:00March 23rd, 2026|Endpoints News|
Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyssnews2026-03-23T11:08:26+00:00March 23rd, 2026|Endpoints News|
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infectionnews2026-03-23T11:01:00+00:00March 23rd, 2026|Endpoints News|
Pfizer’s Lyme disease vaccine trial hampered by lack of casesnews2026-03-23T10:45:45+00:00March 23rd, 2026|Endpoints News|
